Market Overview

Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

Share:

Endologix® Inc. (NASDAQ:ELGX), a developer and marketer of innovative
treatments for aortic disorders, announced today that the EC Certificate
of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing
System (Nellix System) has been suspended by its Notified Body, GMED,
following a voluntary recall and Field Safety Notification (FSN) issued
by Endologix on January 4, 2019.

"The notification from GMED is a regulatory action and is not in
response to any new information beyond our recent FSN," said Dr. Matt
Thompson, Chief Medical Officer of Endologix. "This action is consistent
with our previously articulated plans for the Nellix System and does not
affect other Endologix products. We remain steadfast in our commitment
to patient safety and believe in the transformational potential of
Nellix."

Earlier this month, Endologix announced that the Nellix System will for
the foreseeable future be made available only for use at approved
centers in a clinical investigation setting, with all cases pre-screened
by a physician panel and supported by Endologix to ensure use in
accordance with the current indications and optimal clinical outcomes.

Suspension of the CE Mark means that Endologix may not affix the CE Mark
and sell the Nellix System in the European Union during the term of the
suspension.

Endologix does not expect this action to impact its previously
communicated financial guidance for 2019.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments
for aortic disorders. The Company's focus is in endovascular stent
grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once an AAA develops, it
continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for
ruptured AAA is approximately 80%, making it a leading cause of death in
the U.S. For more information, visit www.endologix.com.

Cautions Regarding Forward-Looking Statements

Except for historical information contained herein, this press
release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements generally can be identified by the use of words such as
"anticipate," "expect," "could," "may," "will," "believe," "estimate,"
"forecast," "goal," "project," "continue," "outlook," "guidance,"
"future," other words of similar meaning and the use of future dates.
Forward-looking statements used in this press release include: limited
availability of the Nellix System in the foreseeable future at approved
centers in a clinical investigation setting to ensure use in accordance
with the current indications and optimal clinical outcomes ; effect of
the CE Mark suspension, and; the expectation that the CE Mark suspension
will not impact Endologix's previously communicated 2019 financial
guidance , the accuracy of which are necessarily subject to risks and
uncertainties that may cause Endologix's actual results to differ
materially and adversely from the statements contained herein. Some of
the potential risks and uncertainties that could cause actual results to
differ materially and adversely from anticipated results include,
continued market acceptance, endorsement and use of Endologix's
products, the success of clinical trials relating to Endologix
's
Nellix System and other products, product research and development
efforts, uncertainty in the process of obtaining and maintaining
regulatory approval for Endologix's products, Endologix's ability to
continue to access the capital markets on terms acceptable to it or at
all, Endologix's ability to remain in compliance with its obligations to
its creditors and other counterparties, Endologix's ability to protect
its intellectual property rights and proprietary technologies, and other
economic, business, competitive and regulatory factors. The
forward-looking statements contained in this press release speak only as
of the date of this press release. Endologix undertakes no obligation to
update any forward- looking statements contained in this press release
to reflect new information, events or circumstances after the date they
are made, or to reflect the occurrence of unanticipated events. Please
refer to Endologix's filings with the Securities and Exchange Commission
including its Annual Report on Form 10-K for the year ended December 31,
2017, and its Quarterly Reports on Form 10-Q for the quarters ended
March 31, 2018
, June 30, 2018, and September 30, 2018 for
more detailed information regarding these risks and uncertainties and
other factors that may cause actual results to differ materially from
those expressed or implied.

View Comments and Join the Discussion!